Tag: 129779-30-2

129779-30-2, (3R,5S)-rel-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

4.00 g of cis-3,5-dimethylpiperazine-1-carboxylic acid ter-butyl ester (prepared according to the method E. Jon Jacobson et. al. J. Med. Chemistry. 1999, Vol. 42,1123-144) in 91 mL of dichloromethane was treated with sodium bicarbonate (4.7 g) followed by addition of cyanogen bromide (7.5 mL). The reaction mixture was heated at reflux overnight, was filtered, and was purified by column chromatography (0 to 50% ethyl acetate/hexanes) to afford 3.9 g of the title compound as a white solid. 1H NMR (CDC13, 300 MHz) delta ppm 1.33 (d, 6H, J = 6.5 Hz), 1.44 (s, 9H), 2.54 (m, 2H), 3.09 (m, 2H), 4.09 (m, 2H); 13C NMR (CDCl3, 75 MHz) 16.70 (2C), 28. 54 (3C), 53.86 (4C), 80.86, 114.10, 154.22.

129779-30-2, 129779-30-2 (3R,5S)-rel-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate 10822535, apiperazines compound, is more and more widely used in various.

Reference£º
Patent; CHIRON CORPORATION; GLAXOSMITHKLINE; WO2004/112793; (2004); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.129779-30-2,(3R,5S)-rel-tert-Butyl 3,5-dimethylpiperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

1-((2S,6R)-2,6-Dimethylpiperazin-1-yl)ethanone; To 1.0 g (4.67 mmol) of commercially available (3S,5R)-tert-butyl 3,5-dimethylpiperazine-1-carboxylate was added 5 mL of dry dichloroethane in a 100 mL round bottom flask equipped with a loose fitting septa. To this mixture was added 2.0 equivalents (9.33 mmol, 1.63 mL) of redistilled N,N-diisopropylethylamine and the flask was cooled to 0 C. To this solution was added 2.0 equivalents (9.33 mmol, 663.0 muL) of acetyl chloride portionwise. The ice bath was then removed and the solution was stirred at room temperature overnight. The crude product was taken up in a separatory funnel, washed with 5 mL of a saturated sodium bicarbonate solution, 5 mL of a brine solution and dried over magnesium sulfate. Evacuation of solvent gave a quantitative yield (1.2 g) of 1, (3S,5R)-tert-butyl 4-acetyl-3,5-dimethylpiperazine-1-carboxylate, as brown oily solid. LC/MS: m/z 257.25, Rf 1.35 min., 90.0% purity. To 75 mgs (0.29 mmmol) of 1 was added 2 mL of 1:1 solution of dichloroethane and trifluoroacetic acid in a 25 mL round bottom flask equipped with a loose fitting septa. The solution was stirred for about 1 hour at room temperature then evacuated to near dryness on a rotary evaporator to give a brown oil. The resulting oil was triturated with diethyl ether to give 65 mg (82% yield) of 2, 1-((2S,6R)-2,6-dimethylpiperazin-1-yl)ethanone, as a tan amorphous solid. 1H NMR (300 MHz, Tetrahydrofurn-d8): delta ppm 1.40 (d, J=7.32 Hz, 6 H), 2.07 (s, 3 H), 3.13 (dd, J=12.99, 5.31 Hz, 2 H), 3.28-3.38 (m, 2 H), 4.56 (br s, 1 H).

As the paragraph descriping shows that 129779-30-2 is playing an increasingly important role.

Reference£º
Patent; Bristol-Myers Squibb Company; US2007/78122; (2007); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics